{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:09:15Z","timestamp":1794650955413,"version":"4.9.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      Prostate cancer treatment with\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 depends on specific binding to the PSMA protein. If receptors become saturated by the radioligand, the uptake of the drug may be affected. Our goal was to measure the pharmacological effect of standard 7.4\u00a0GBq (200\u00a0mCi) administration of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 based on the uptake of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 on subsequent PET.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      We performed\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT within 0.5\u201375 hours after cycle 1 of therapy administration in 6 patients with metastatic castrate-resistant prostate cancer who volunteered for imaging. SUV\n                      <jats:sub>mean<\/jats:sub>\n                      of tumors (N=27) and organs, stratified by early (&lt;2\u00a0h) and late (~3\u00a0d) post-therapy PET imaging, were compared with baseline PET.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      There were large decreases in SUV\n                      <jats:sub>mean<\/jats:sub>\n                      for tumor, kidney, parotid gland, and liver among patients imaged early after therapy, with an average change in tumor SUV of \u221245% (95% CI: \u221266% to \u221225%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). In contrast, only mild persistent declines in SUV were observed in those scanned late, with an average change in tumor SUV of \u22129% (95% CI: \u221233% to 16%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.42).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      There are measurable decreases in PSMA binding following\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 that resolve over time. As trials consider alternative therapeutic strategies, increasing dosage per cycle alone may not proportionally increase tumor uptake. Our findings warrant validation with a larger number of subjects, standardized post-therapy scan timing, and advanced pharmacokinetic analyses.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006302","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T21:01:06Z","timestamp":1772485266000},"page":"316-319","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Assessing PSMA Receptor Availability Using 68Ga-PSMA-11 PET\/CT Following 177Lu-PSMA-617 Therapy Administration"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-1487","authenticated-orcid":false,"given":"Molly E.","family":"Roseland","sequence":"first","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6894-3443","authenticated-orcid":false,"given":"Kellen J.","family":"Fitzpatrick","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Lu","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-3536","authenticated-orcid":false,"given":"Krithika","family":"Suresh","sequence":"additional","affiliation":[{"name":"Biostatistics and Radiation Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8471-4988","authenticated-orcid":false,"given":"Benjamin L.","family":"Viglianti","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0837-7816","authenticated-orcid":false,"given":"Ka Kit","family":"Wong","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk A.","family":"Frey","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuni K.","family":"Dewaraja","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"R1-20260305","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.3390\/biomedicines10123020","article-title":"Pharmacological optimization of PSMA-based radioligand therapy","volume":"10","author":"Van Der Gaag","year":"2022","journal-title":"Biomedicines"},{"key":"R2-20260305","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with177 Lu-Labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"R3-20260305","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.nucmedbio.2019.05.003","article-title":"Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands","volume":"72\u201373","author":"Winter","year":"2019","journal-title":"Nucl Med Biol"},{"key":"R4-20260305","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2967\/jnumed.118.210377","article-title":"Modeling and predicting tumor response in radioligand therapy","volume":"60","author":"Kletting","year":"2019","journal-title":"J Nucl Med"},{"key":"R5-20260305","doi-asserted-by":"crossref","first-page":"824","DOI":"10.2967\/jnumed.124.269111","article-title":"Determining PSMA-617 mass and molar activity in pluvicto doses","volume":"66","author":"Wang","year":"2025","journal-title":"J Nucl Med"},{"key":"R6-20260305","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution","volume":"19","author":"Ferreira","year":"2019","journal-title":"Cancer Imaging"},{"key":"R7-20260305","doi-asserted-by":"crossref","first-page":"1373606","DOI":"10.3389\/fonc.2024.1373606","article-title":"Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review","volume":"14","author":"Yan","year":"2024","journal-title":"Front Oncol"},{"issue":"16_suppl","key":"R8-20260305","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2024.42.16_suppl.5074","article-title":"Final results of a phase I\/II dose-escalation study of fractionated dose 177 Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)","volume":"42","author":"Tagawa","year":"2024","journal-title":"J Clin Oncol"},{"key":"R9-20260305","doi-asserted-by":"crossref","first-page":"20221178","DOI":"10.1259\/bjr.20221178","article-title":"Prospective inter- and intra-tracer repeatability analysis of radiomics features in [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET scans in metastatic prostate cancer","volume":"96","author":"Kendrick","year":"2023","journal-title":"Br J Radiol"},{"key":"R10-20260305","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2967\/jnumed.122.264101","article-title":"The impact of peptide amount on tumor uptake to assess PSMA receptor saturation on 68 Ga-PSMA-11 PET\/CT in patients with primary prostate cancer","volume":"64","author":"Siebinga","year":"2023","journal-title":"J Nucl Med"},{"key":"R11-20260305","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions","volume":"56","author":"Afshar-Oromieh","year":"2015","journal-title":"J Nucl Med"},{"key":"R12-20260305","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20260305","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13550-020-0594-6","article-title":"Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients","volume":"10","author":"Ringheim","year":"2020","journal-title":"EJNMMI Res"},{"key":"R14-20260305","doi-asserted-by":"crossref","first-page":"20041","DOI":"10.1038\/s41598-019-56603-8","article-title":"The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: a simulation study using a PBPK model","volume":"9","author":"Begum","year":"2019","journal-title":"Sci Rep"},{"issue":"suppl 2","key":"R15-20260305","first-page":"242514","article-title":"High photon emission rate effects on PET\/CT using Lu-177, a phantom study","volume":"65","author":"Sennung","year":"2024","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:03:07Z","timestamp":1772744587000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006302","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"2025-09-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}